Mirae Asset Global Investments Co. Ltd. Grows Stake in Gilead Sciences, Inc. $GILD

Mirae Asset Global Investments Co. Ltd. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 610,834 shares of the biopharmaceutical company’s stock after buying an additional 54,068 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Gilead Sciences were worth $67,803,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. GoalVest Advisory LLC boosted its holdings in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Corundum Trust Company INC purchased a new stake in Gilead Sciences during the 3rd quarter worth $26,000. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences in the 2nd quarter worth $27,000. Putney Financial Group LLC boosted its position in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences during the second quarter valued at about $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on GILD. Wolfe Research reissued an “outperform” rating and issued a $150.00 price target on shares of Gilead Sciences in a report on Monday, December 15th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Truist Financial lifted their price target on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday. Daiwa Capital Markets increased their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Finally, Citigroup boosted their target price on shares of Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $135.36.

Gilead Sciences Stock Down 0.9%

Shares of NASDAQ:GILD opened at $139.72 on Thursday. The company’s fifty day moving average is $124.76 and its two-hundred day moving average is $119.24. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $141.71. The stock has a market capitalization of $173.35 billion, a price-to-earnings ratio of 21.66, a price-to-earnings-growth ratio of 0.74 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.02 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Phase‑3 Trodelvy combo beat Keytruda + chemo in a pivotal study, sparking a sharp rally and renewed bullish debate about Gilead’s oncology upside. Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial
• Positive Sentiment: Multiple analyst upgrades/price‑target raises (Citigroup to $156, Truist, BMO, UBS commentary) are reinforcing buy-side momentum and likely supporting higher valuations in the near term. Citigroup adjusts price target on Gilead Sciences to 156 from 140; maintains buy rating
• Neutral Sentiment: Gilead will report Q4 & full‑year 2025 results on Feb 10 — a clear near‑term catalyst that could amplify either the positive trial reaction or reveal operational headwinds. Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
• Neutral Sentiment: News aggregator and investor‑attention pieces (Zacks, sector writeups) are boosting visibility but are not new fundamental information. Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Short‑interest data in the feed shows zero shares/NaN (likely a reporting artifact) — not a reliable signal for positioning or squeeze risk today.
• Negative Sentiment: CEO Daniel O’Day sold 115,640 shares (~$15.6M) in late January, reducing his holding ~17% — a notable insider sale that market participants may view as a short‑term negative or liquidity event. SEC filing: Form 4 — Daniel Patrick O’day sale

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the transaction, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the transaction, the insider directly owned 107,193 shares in the company, valued at $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 247,397 shares of company stock valued at $31,986,612. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.